Latest News

event-image
23 May 2024

Clexio announces 50% enrollment milestone reached, in CLE-400 Phase 2 proof-of-concept study, in subjects suffering from chronic pruritus associated with Notalgia Paresthetica

event-image
15 April 2024

Clexio Biosciences expands its protection of CLE-100 with the issuance of a third US method of use patent and the allowance of an additional three US patents

event-image
10 April 2024

Clexio initiates enrolment in SOLEO Study, a Phase 2 study assessing the safety and efficacy of CLE-100 as an adjunctive treatment in subjects with Major Depressive Disorder

event-image
4 April 2024

Clexio presents CLEO trial results at Oxford Conference on Ketamine and Related Compounds

event-image
15 February 2024

Clexio Biosciences receives second US method of use patent for CLE-400

event-image
5 February 2024

Clexio initiates Phase 2 Proof of Concept Study to assess efficacy and Safety of CLE-400 gel for the treatment of Notalgia Paresthetica

event-image
15 January 2024

Clexio Biosciences receives second US method of use patent for CLE-100

event-image
15 November 2023

Clexio presents CLE-400; Topical Alpha-2-Adrenergic Agonist as a First-in-Class Treatment for Localized Chronic Pruritus at the 7th Annual Dermatology Drug Development Summit

event-image
10 November 2023

Clexio receives FDA IND clearance for a Phase 2 POC study evaluating CLE-400, a novel topical therapy for localized chronic pruritus. Final protocol submitted.

event-image
15 May 2023

Clexio presents results of CLEO study “A Phase 2 Randomized Controlled Adjunctive Treatment Trial With CLE-100 Esketamine Tablet in Patients with Major Depressive Disorder (MDD) with Inadequate Response to Antidepressants” at American Society of Clinical Psychopharmacology Annual Meeting (ASCP 2023)

event-image
13 January 2023

Clexio Biosciences expands its proprietary OLAR platform with issuance of ninth US patent

event-image
15 February 2022

Successful Completion of Phase 1 Multiple Ascending Dose Clinical Trial of the CLE-400 topical gel

Skip to content